Publications

Last changed: 07 June 2017

Rivera P, Akerlund-Denneberg N, Bergvall K, Kessler M, Rowe A, Willmann M, Persson G, Kastengren Fröberg G, Westberg S, von Euler H.
J Small Anim Pract. 2013 Jan;54(1):20-7. doi: 10.1111/j.1748-5827.2012.01304.x. Epub 2012 Nov 27.
Clinical efficacy and safety of a water-soluble micellar paclitaxel (Paccal Vet) in canine mastocytomas.
PubMed, PDF.

Stålhandske P, Wang L, Westberg S, von Euler H, Groth E, Gustafsson SA, Eriksson S, Lennerstrand J.
Anal Biochem. 2013 Jan 15;432(2):155-64. doi: 10.1016/j.ab.2012.08.004. Epub 2012 Aug 14 Homogeneous assay for real-time and simultaneous detection of thymidine kinase 1 and deoxycytidine kinase activities.
PubMed, PDF.

Taylor SS, Dodkin S, Papasouliotis K, Evans H, Graham PA, Belshaw Z, Westberg S, von Euler HP.
J Feline Med Surg. 2012 Oct 17. [Epub ahead of print]
Serum thymidine kinase activity in clinically healthy and diseased cats: a potential biomarker for lymphoma.
PubMed, PDF.

Vail DM, von Euler H, Rusk AW, Barber L, Clifford C, Elmslie R, Fulton L, Hirschberger J, Klein M, London C, Martano M, McNiel EA, Morris JS, Northrup N, Phillips B, Polton G, Post G, Rosenberg M, Ruslander D, Sahora A, Siegel S, Thamm D, Westberg S, Winter J, Khanna C.
J Vet Intern Med. 2012 May-Jun;26(3):598-607. doi: 10.1111/j.1939-1676.2012.00897.x. Epub 2012 Mar 6.
A randomized trial investigating the efficacy and safety of water soluble micellar paclitaxel (Paccal Vet) for treatment of nonresectable grade 2 or 3 mast cell tumors in dogs.
PubMed, PDF.

von Euler H, Rivera P, Nyman H, Häggström J, Borgå O.
Vet Comp Oncol. 2012 Mar 9. doi: 10.1111/j.1476-5829.2011.00314.x. [Epub ahead of print]
A dose-finding study with a novel water-soluble formulation of paclitaxel for the treatment of malignant high-grade solid tumours in dogs.
PubMed, PDF.

von Euler H, Eriksson S.
Vet Comp Oncol. 2011 Mar;9(1):1-15. doi: 10.1111/j.1476-5829.2010.00238.x. Epub 2010 Aug 19. Comparative aspects of the proliferation marker thymidine kinase 1 in human and canine tumour diseases.
PubMed, PDF.

Rivera P, von Euler H.
Vet Pathol. 2011 Jan;48(1):132-46. Epub 2010 Dec 7. Molecular biological aspects on canine and human mammary tumors.
PubMed, PDF.

Rivera P, Melin M, Biagi T, Fall T, Häggström J, Lindblad-Toh K, von Euler H.
Cancer Res. 2009 Nov 15;69(22):8770-4. Epub 2009 Nov 3. Mammary tumor development in dogs is associated with BRCA1 and BRCA2.
PubMed, PDF.

Lee JJ, Larsson C, Lui WO, Hoog A, von Euler H. A dog pedigree with familial medullary thyroid cancer. Int J Oncol. 2006 Nov;29(5):1173-82.
PubMed, PDF.

von Euler H, Khoshnoud R, He Q, Khoshnoud A, Fornander T, Rutqvist LE, Skog S.  Time-dependent RNA degradation affecting cDNA array quality in spontaneous canine tumours sampled using standard surgical procedures. Int J Mol Med. 2005 Dec;16(6):979-85.
PubMed, PDF.

von Euler HP, Ohrvik AB, Eriksson SK. A non-radiometric method for measuring serum thymidine kinase activity in malignant lymphoma in dogs. Res Vet Sci. 2006 Feb;80(1):17-24.
PubMed, PDF.

Egenvall A, Bonnett BN, Ohagen P, Olson P, Hedhammar A, von Euler H. Incidence of and survival after mammary tumors in a population of over 80,000 insured female dogs in Sweden from 1995 to 2002. Prev Vet Med. 2005 Jun 10;69(1-2):109-27.
PubMed, PDF.

von Euler H, Einarsson R, Olsson U, Lagerstedt AS, Eriksson S. Serum thymidine kinase activity in dogs with malignant lymphoma: a potent marker for prognosis and monitoring the disease. J Vet Intern Med. 2004 Sep-Oct;18(5):696-702.
PubMed, PDF.

Commented in: Madewell BR. Serum thymidine kinase activity: an alternative to histologic markers of cellular proliferation in canine lymphoma. J Vet Intern Med. 2004 Sep-Oct;18(5):595-6
PubMed, PDF.

 

For the most updated reference list please search Medline on von Euler H or Medline on Ronnberg H.


Contact